Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Yatsevich (Minsk, Belarus), I. Adzerikho (Minsk, Belarus), ?. Vladimirskaja (Minsk, Belarus), G. Semenkova (Minsk, Belarus). Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH).. 1487

Member's Comments

No comment yet.

Related content which might interest you: Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Source: Eur Respir J 2011; 37: 813-822 Year: 2011 Copper restriction prevents and reverses angioproliferation in experimentally induced pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension Year: 2009 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Macitentan modulates pulmonary mRNA levels of gremlin 1 in a rat model of pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Treatment effects of Rho-kinase (Rock) inhibition vs. phosphodiesterase-5 (PDE5) inhibition on cardiac function and metabolism in monocrotaline induced pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Human apyrase (APT102) treatment attenuates the development of severe pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Role of tadalafil in patients with hypoxia / lung disease induced (group 3) pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Simvastatin and sildenafil combine to attenuate pulmonary hypertension Source: Eur Respir J 2009; 34: 948-957 Year: 2009 Pulmonary artery pressure (PAP) reduction by systemic and inhaled nitroglycerin (NTG) in an isolated rabbit lung model of pulmonary hypertension (PH) Source: Eur Respir J 2003; 22: Suppl. 45, 270s Year: 2003 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020